Viscoelastic substance in prefilled syringe as an etiology of Toxic Anterior Segment Syndrome.

CONTEXT: Toxic Anterior Segment Syndrome (TASS) is an acute postoperative inflammatory reaction in which a noninfectious substance enters the anterior segment and induces toxic damage to the intraocular tissues. OBJECTIVE: To present etiologic investigation of two consecutive clusters of TASS. TASS outbreak and investigation: This paper presents two consecutive clusters of TASS in 15 of the 24 uneventful surgeries and the investigation carried out to find the etiology. After the occurrence of first cluster of TASS, sterilization-related etiology was explored; however, we did not find any lacunae in the sterilization and cleaning process in the operating theater (OT). Nevertheless, multiple changes in cleaning process were implemented. Still a second cluster of TASS was encountered in the following session of OT. Several other factors which include preservatives, hand gloves, intraocular lenses, medications/solutions, intraocular penetration of topically administered drugs, and viscoelastics were investigated as the possible etiology of the second consecutive cluster of TASS; however, most of them were ruled out. The newly introduced viscoelastic I-visc® 1.4% sodium hyaluronate (I medical, i-Medical Ophthalmic International GmbH, Heidelberg, Germany) was thought to be the most likely cause and was replaced with previously in use sodium hyaluronate 1.5% and lidocaine hydrochloride 1% (Visthesia, CZ, Germany) in the following session of OT. No further TASS incident was encountered after replacing the viscoelastic. CONCLUSION: Investigation revealed that 1.4% sodium hyaluronate in prefilled syringe (PFS) (I-visc® 1.4%) was the etiologic factor of two consecutive clusters of TASS. While TASS due to residual denatured ophthalamic viscosurgical devices (OVDs) is a common knowledge, current study brings out that even disposable viscoelastic material supplied in PFSs can be an etiology of TASS. It is important to recognize that contamination of OVDs with endotoxins can occur at the time of manufacturing. Therefore, in the absence of appropriate guidelines for ophthalmic preparations, endotoxin limit for medical preparations (i.e. <0.5 endotoxin units/ml) must be considered during OVD manufacture.

Reproducibility of flap thickness in sub-Bowman keratomileusis using a mechanical microkeratome.

PURPOSE: To examine the predictability of flap thickness using a mechanical microkeratome (One Use-Plus) and identify factors related to variations in flap thickness in sub-Bowman keratomileusis (SBK). SETTING: Tadawi Surgical Center, Taif, Saudi Arabia. DESIGN: Retrospective case series. METHODS: Patients with a stable refraction for 1 year, corrected distance visual acuity (CDVA) of at least 20/20 in each eye, and minimum central corneal thickness of 480 µm in each eye had microkeratome-assisted SBK. Parameters included manifest refraction, uncorrected distance visual acuity (UDVA), CDVA, pachymetry, and higher-order aberrations (HOAs). RESULTS: Seventy eyes (36 patients) were enrolled. The mean flap thickness was 88.74 µm ± 15.40 (SD) and the mean change in HOAs, 0.11 ± 0.30 µm(2). There was no correlation between flap thickness and age (r = -0.10), preoperative manifest refraction spherical equivalent (MRSE) (r = -0.08), preoperative cylinder (r = 0.13), postoperative CDVA (r = -0.17), or postoperative change in HOAs (r = -0.07). A strong positive correlation with preoperative pachymetry (r = 0.41) and a weak negative correlation with preoperative sphere (r = -0.21) were observed. There was no or a moderate negative correlation of pachymetry with age (r = -0.14), preoperative sphere (r = -0.36), cylinder (r = -0.04), or MRSE (r = -0.36). CONCLUSIONS: The microkeratome was reliable with reasonable predictability for SBK flap creation. Extra caution in handling the flaps to avoid flap striae or tears is advised. Flap thickness correlated positively with preoperative pachymetry; however, the variation in flap thickness did not affect visual outcomes. FINANCIAL DISCLOSURE: The author has no financial or proprietary interest in any material or method mentioned.

Posterior chamber toric phakic IOL implantation for the management of pediatric anisometropic amblyopia.

PURPOSE: To report the outcomes of toric posterior chamber phakic intraocular lens (PIOL) implantation in children for the treatment of amblyopia due to anisometropia with astigmatism. METHODS: Six eyes of 6 amblyopic patients aged 5 to 15 years underwent toric PIOL (Visian Toric ICL; STAAR Surgical Company, Monrovia, CA) implantation for refractory anisometropic amblyopia. Preoperative and postoperative clinical evaluation included slit-lamp microscopy, visual acuity, anterior/posterior segment examination, and cycloplegic refraction. RESULTS: After a mean follow-up of 23 months (range: 15 to 34 months), mean spherical equivalent cycloplegic refraction improved from -10.21 ± 4.62 diopters (D) (range -7.5 to -19.5 D) preoperatively to -0.42 ± 0.39 D (range: -0.625 to +0.125 D) postoperatively. Corrected distance visual acuity ranged from 20/40 to 20/200 preoperatively and 20/20 to 20/60 postoperatively. Five of the 6 eyes gained more than 3 lines of corrected distance visual acuity with a maximum gain of 8 lines in one eye. One eye showed an improvement of more than 2 lines (change in preoperative visual acuity of 20/100 to 20/60 postoperatively). No patients lost any lines of visual acuity. All eyes remained quiet. All PIOLs remained well centered throughout the follow-up period. CONCLUSION: Toric PIOL implantation may be a viable therapeutic modality in children with clinically significant anisometropic ametropia and astigmatism with secondary amblyopia who have been refractory to medical treatment including spectacles or contact lenses. Longer follow-up visits with larger sample populations will evaluate more effectively the long-term efficacy and late-onset of complications.